{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-26-000068","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2026-07-01T20:08:37+00:00","discovered_at":"2026-07-01T20:09:00.346649+00:00","generated_at":"2026-07-01T20:09:18.141485+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biogen expects Q2 IPR&D charge of ~$164M ($0.95/share) and Q3 charge of $290M-$320M ($1.75-$1.95/share)","bullets":["Q2 2026: ~$164M pre-tax IPR&D charge; EPS impact ~$0.95 per share.","Q3 2026: $290M-$320M pre-tax IPR&D charge; EPS impact $1.75-$1.95 per share.","Charges relate to collaboration and license agreements, including upfront and milestone payments.","Results for Q2 2026 not finalized; subject to financial closing procedures.","Company does not forecast such expenses due to uncertainty of future transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-26-000068","json":"https://secwatch.observer/filing/0000875045-26-000068.json","markdown":"https://secwatch.observer/filing/0000875045-26-000068.md","text":"https://secwatch.observer/filing/0000875045-26-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/0000875045-26-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T20:09:18.141485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}